Literature DB >> 24421505

Mitomycin and Fluorouracil With Concurrent Radiation (FUMIR) Regimen for Anal Cancer.

Brittany N White1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421505      PMCID： PMC3839500          DOI： 10.1310/hpj4806-464

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  18 in total

Review 1.  Hepatotoxicity of chemotherapy.

Authors:  P D King; M C Perry
Journal:  Oncologist       Date:  2001

2.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

3.  Combined chemoradiation therapy for anal cancer. A report of 56 cases.

Authors:  R Doci; R Zucali; L Bombelli; F Montalto; G Lamonica
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

4.  Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.

Authors:  B J Cummings; T J Keane; B O'Sullivan; C S Wong; C N Catton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-10       Impact factor: 7.038

5.  Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study.

Authors:  Té Vuong; Slobodan Devic; Paul Belliveau; Thierry Muanza; Gyorgy Hegyi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

6.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

7.  Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma.

Authors:  Nicola Raffetto; Alessia Monaco; Enzo Banelli
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

Review 8.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

9.  Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups.

Authors:  J F Bosset; F Roelofsen; D A L Morgan; V Budach; P Coucke; J J Jager; E Van der Steen-Banasik; N Trivière; G Stüben; M Puyraveau; M Mercier
Journal:  Eur J Cancer       Date:  2003-01       Impact factor: 9.162

10.  Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.

Authors:  J A Maroun; L B Anthony; N Blais; R Burkes; S D Dowden; G Dranitsaris; B Samson; A Shah; M P Thirlwell; M D Vincent; R Wong
Journal:  Curr Oncol       Date:  2007-02       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.